MRK vs PFE: fair value comparison
Merck & Co., Inc. and Pfizer Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, MRK currently sits closer to the top of our discount ranking. MRK carries the stronger quality grade.
| MRK | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $148.35 | $27.96 |
| 12-month range | $82.49–$130.20 | $24.23–$28.55 |
| Sector rank | #95 of 113 Healthcare | #100 of 113 Healthcare |
| Quality grade | C | F |
| Momentum grade | A | A |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: MRK fair value analysis · PFE fair value analysis